Correction of thrombohemorrhagic syndrome in patients with widespread soft tissue phlegmon and sepsis

E. A. Tseimakh, V. Zinchenko, O. Lavrinenko, V. Chernenko, A. Kalashnikov, E. Shalabod, M. E. M. Tseimakh
{"title":"Correction of thrombohemorrhagic syndrome in patients with widespread soft tissue phlegmon and sepsis","authors":"E. A. Tseimakh, V. Zinchenko, O. Lavrinenko, V. Chernenko, A. Kalashnikov, E. Shalabod, M. E. M. Tseimakh","doi":"10.17709/2410-1893-2022-9-1-7","DOIUrl":null,"url":null,"abstract":"Purpose of the study. Analysis of the effectiveness of cryoprecipitate – antienzymatic with common soft tissue phlegmon and sepsis.Patients and methods. To achieve the intended goal, a study of the results of treatment of 92 patients with a diagnosis of advanced soft tissue phlegmon and sepsis was performed. All patients underwent a comprehensive diagnostic study with an in-depth study of the indicators of the hemostasis system. For a comparative assessment, 2 groups of patients were identified. Group 1 (46 (50 %) patients – the main one) – received cryoprecipitate-antienzymatic therapy as part of complex treatment, group 2 (46 (50 %) patients – comparisons) – received only the generally accepted basic treatment.Results. An in-depth study of the hemostasis system in patients with widespread soft tissue phlegmon and sepsis indicated the development of thrombohemorrhagic syndrome, which was manifested by depletion of both the coagulation and anticoagulation systems of the blood, a drop in AT III, an increase in thrombinemia and fibrinolysis depression. In order to correct thrombohemorrhagic syndrome, a cryoprecipitate-antienzymatic complex was included in the complex treatment of patients with widespread soft tissue phlegmons and sepsis, aimed at unblocking microcirculation in inflammatory foci and parenchymal organs, to improve the penetration of antibacterial drugs and other drugs into these foci, thereby stopping inflammation and preventing the increase of multiple organ failure. The effectiveness of the cryoprecipitate-antienzymatic complex was evaluated based on clinical data of the course of the purulent – inflammatory process and the results of indicators of the hemocoagulation and fibrinolysis system on 8–10 days from the start of therapy.Conclusion. The use of cryoprecipitate-antienzymatic complex, which includes freshly frozen plasma (FFP), heparin, proteinase inhibitors, in patients with widespread soft tissue phlegmon and sepsis effectively eliminates thrombohemorrhagic syndrome, which improves microcirculation in purulent – inflammatory foci and affected parenchymal organs, improving the flow of antibacterial drugs into these foci. At the same time, there is an improvement in the course of the wound process, so the wounds are cleaned faster from necrotic masses and filled with healthy granulation tissue, which makes it possible to perform plastic closure of the wound defect 1.6 times faster. Mortality is reduced by 2.2 times and the number of thrombotic and thromboembolic complications in the structure of deaths is reduced.","PeriodicalId":334809,"journal":{"name":"Research and Practical Medicine Journal","volume":"73 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Practical Medicine Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17709/2410-1893-2022-9-1-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of the study. Analysis of the effectiveness of cryoprecipitate – antienzymatic with common soft tissue phlegmon and sepsis.Patients and methods. To achieve the intended goal, a study of the results of treatment of 92 patients with a diagnosis of advanced soft tissue phlegmon and sepsis was performed. All patients underwent a comprehensive diagnostic study with an in-depth study of the indicators of the hemostasis system. For a comparative assessment, 2 groups of patients were identified. Group 1 (46 (50 %) patients – the main one) – received cryoprecipitate-antienzymatic therapy as part of complex treatment, group 2 (46 (50 %) patients – comparisons) – received only the generally accepted basic treatment.Results. An in-depth study of the hemostasis system in patients with widespread soft tissue phlegmon and sepsis indicated the development of thrombohemorrhagic syndrome, which was manifested by depletion of both the coagulation and anticoagulation systems of the blood, a drop in AT III, an increase in thrombinemia and fibrinolysis depression. In order to correct thrombohemorrhagic syndrome, a cryoprecipitate-antienzymatic complex was included in the complex treatment of patients with widespread soft tissue phlegmons and sepsis, aimed at unblocking microcirculation in inflammatory foci and parenchymal organs, to improve the penetration of antibacterial drugs and other drugs into these foci, thereby stopping inflammation and preventing the increase of multiple organ failure. The effectiveness of the cryoprecipitate-antienzymatic complex was evaluated based on clinical data of the course of the purulent – inflammatory process and the results of indicators of the hemocoagulation and fibrinolysis system on 8–10 days from the start of therapy.Conclusion. The use of cryoprecipitate-antienzymatic complex, which includes freshly frozen plasma (FFP), heparin, proteinase inhibitors, in patients with widespread soft tissue phlegmon and sepsis effectively eliminates thrombohemorrhagic syndrome, which improves microcirculation in purulent – inflammatory foci and affected parenchymal organs, improving the flow of antibacterial drugs into these foci. At the same time, there is an improvement in the course of the wound process, so the wounds are cleaned faster from necrotic masses and filled with healthy granulation tissue, which makes it possible to perform plastic closure of the wound defect 1.6 times faster. Mortality is reduced by 2.2 times and the number of thrombotic and thromboembolic complications in the structure of deaths is reduced.
广泛软组织痰和脓毒症患者血栓出血性综合征的纠正
研究目的:低温沉淀抗酶治疗常见软组织痰脓毒症的疗效分析。患者和方法。为了达到预期的目标,对92例诊断为晚期软组织痰和脓毒症的患者的治疗结果进行了研究。所有患者均进行了全面的诊断研究,并对止血系统指标进行了深入的研究。为了进行比较评估,我们确定了两组患者。第1组(46例(50%)患者-主要患者)-接受低温沉淀-抗酶治疗作为综合治疗的一部分,第2组(46例(50%)患者-比较)-只接受普遍接受的基础治疗。对广泛存在的软组织痰和脓毒症患者的止血系统的深入研究表明血栓出血综合征的发展,其表现为血液凝血和抗凝血系统的衰竭,AT III下降,凝血酶血症增加和纤溶抑制。为了纠正血栓出血性综合征,将低温沉淀-抗酶复合物纳入广泛存在的软组织痰脓毒症患者的综合治疗中,旨在疏通炎症灶和实质器官的微循环,提高抗菌药物等药物对这些灶的渗透,从而停止炎症,防止多器官衰竭的增加。根据治疗开始后8-10天的化脓性炎症过程的临床资料和凝血、纤溶系统指标的结果来评价低温沉淀-抗酶复合物的有效性。低温沉淀-抗酶复合物,包括新鲜冷冻血浆(FFP),肝素,蛋白酶抑制剂,在广泛的软组织痰和脓毒症患者中使用,有效消除血栓出血性综合征,改善化脓性炎症灶和受影响的实质器官的微循环,改善抗菌药物流入这些灶。同时,在创面过程中也有了改进,创面坏死团块的清理速度更快,创面内充满健康的肉芽组织,创面缺损的塑料缝合速度提高了1.6倍。死亡率降低了2.2倍,在死亡结构中血栓和血栓栓塞并发症的数量减少了。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信